Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid MalignanciesRomain Guièze, Catherine J. Wu, Vivian M. Liu et al.|Cancer Cell|2019Cited by 361
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicityBenjamin L. Lampson, Jennifer R. Brown, Siddha Kasar et al.|Blood|2016Cited by 289
Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemiaJing Deng, Matthew S. Davids, Stacey M. Fernandes et al.|Leukemia|2017Cited by 199
Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndromeErin M. Parry, Jennifer R. Brown, Ignaty Leshchiner et al.|Nature Medicine|2023Cited by 83
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistanceAishath Naeem, Jennifer R. Brown, Filippo Utro et al.|Blood Advances|2022Cited by 79